Physician profile
Ramesh Annadurai
NPI 1396976379
$1,365.48
in general payments reported to CMS, 2019-2025
29 companies · $207 in 2025
The $207 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $463 · 2020: $99.16 · 2021: $12.68 · 2022: $146 · 2023: $255 · 2024: $182 · 2025: $207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $628 · Education: $16.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $627.79 |
| Education | $16.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $282.81 | 2022-2025 | |
| Aurinia Pharma U.S., INC. | $173.04 | 2023-2024 | Lupkynis |
| Amgen INC. | $81.18 | 2019-2025 | Tavneos |
| Novartis Pharmaceuticals Corporation | $74.59 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $57.68 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $50.86 | 2019-2023 | Farxiga |
| Genzyme Corporation | $49.58 | 2019-2020 | |
| Vifor Pharma, INC. | $48.29 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $46.42 | 2019-2025 | Ultomiris |
| Horizon Therapeutics Plc | $44.73 | 2019-2020 | |
| Lundbeck LLC | $40.44 | 2019-2020 | |
| Daiichi Sankyo INC. | $40.24 | 2019 | |
| Ardelyx, INC. | $39.10 | 2023-2025 | Ibsrela |
| Baxter Healthcare | $38.39 | 2019 | |
| Novo Nordisk INC | $38.21 | 2023-2024 | Ozempic |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $27.96 | 2019-2021 | |
| Calliditas Therapeutics US INC. | $25.22 | 2025 | Tarpeyo |
| Akebia Therapeutics INC | $21.79 | 2019 | |
| Shire North American Group INC | $21.34 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $21.13 | 2024 | Crysvita |
| Janssen Pharmaceuticals, INC | $19.55 | 2019 | |
| Apellis Pharmaceuticals, INC. | $17.73 | 2025 | Empaveli |
| Travere Therapeutics, INC. | $16.42 | 2023-2025 | Filspari |
| Genentech USA, INC. | $15.97 | 2019 | |
| Fresenius USA Marketing, INC. | $15.88 | 2019 | |
| Glaxosmithkline, LLC. | $15.34 | 2023 | Benlysta |
| Mallinckrodt Enterprises LLC | $15.28 | 2019 | |
| Nxstage Medical, INC. | $15.11 | 2025 | Pureflow Sl, Nxstage System One |
| Outset Medical INC | $11.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramesh Annadurai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.